Bing

SEARCH HISTORY

Celldex Therapeutics Inc. (CLDX) announced final results from its Phase 2b study ... Goodyear Tire & Rubber Co. (GT) will transfer its stock-exchange listing to the Nasdaq from the New York Stock Exchange, the latest move in the heated battle for …
The Wall Street Journal · ByAnna Prior · 12/10/2012
Gilead - The Sovaldi (SOF) [chronic hepatitis C (HCV)] launch continuing to exceed high expectations and idelalisib non-Hodgkin's lymphoma (NHL) approval should drive the stock higher. We project $2.7 billion SOF sales in 2014, which we believe may be ...
Barron's · 1/12/2014
The stock I like now is Celldex (CLDX); another one is ACAD. SPEAKER 1: What’s that one? HARRY: Arcadia pharmaceuticals. SPEAKER 1: Okay. HARRY: They’re emerging and they’re in their 20s. I think if they can be $40, $50, $60 a stock
The Money Show · 9/29/2013
More from Bing News
Steve Brozak: The problem I have with looking at these new therapeutic modalities as investments is that they don’t lend themselves to general biotech stock and index buying ... Celldex Therapeutics Inc. (CLDX:NASDAQ) with you in the past.
Trefis · 6/8/2015
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s) U.S. stock index futures ... CELLDEX THERAPEUTICS INC (NasdaqGS: CLDX - news) …
Yahoo Finance UK and Ireland · 2/23/2015
NEW YORK, NY / ACCESSWIRE / April 23, 2015 / Cancer immunotherapy is scorching ... is valued by investors at $7.4 billion. Celldex Therapeutics (CLDX:NASDAQ), in mid-stage trials for brain cancer using immunotherapy would, if successful, sell to a …
BayStreet · 4/23/2015
The Biotech Investor has continued to show impressive growth in 2013. On Wednesday, the Nasdaq Biotechnology Index reached a record high and has gained approximately 43.0 percent year-to-date. Additionally the iShares NASDAQ Biotechnology Index …
Finance Yahoo · 9/6/2013
The company traded at $6.20 + 0.70 (12.73 pct) on 1,254,773 total share volume. Celldex Therapeutics Inc. (CLDX) has hit a new high of 29.50 above a previous 52-week high of 28.45. The company traded at $29.44 + 3.07 (11.63 pct) on 4,684,003 total share ...
Fx Pips · 3/5/2015
Celldex Therapeutics, Inc. (NASDAQ:CLDX) gained 28.88%, the company recently announced an interim update from the Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM). The ReACT results demonstrate clear signs of clinical …
istreetwire.com · 11/18/2014
HAMPTON, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib …
CNN Money · 5/28/2015